Companies:
49,998
Total Market Cap:
142334588069207.95
Global Rank
#19003
Country Rank
#107
Market Cap
248.57 M
Price
3.23
Change (%)
0.73%
Volume
101,870
Oryzon Genomics S.A.'s latest marketcap:
248.57 M
As of 07/28/2025, Oryzon Genomics S.A.'s market capitalization has reached $248.57 M. According to our data, Oryzon Genomics S.A. is the 19003th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 248.57 M |
| Revenue (ttm) | 8.58 M |
| Net Income (ttm) | -4,918,329.94 |
| Shares Out | 77.51 M |
| EPS (ttm) | -0.08 |
| Forward PE | 14.18 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/21/2025 |
Market Cap Chart
Data Updated: 07/28/2025
Oryzon Genomics S.A.'s yearly market capitalization.
Oryzon Genomics S.A. has seen its market value grow from €95.48 M to €213.16 M since 2015, representing a total increase of 123.26% and an annual compound growth rate (CAGR) of 8.75%.
| Date | Market Cap(€) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/28/2025 | €213.16 M | $248.57 M | 135.29% | 19003 |
| 12/31/2024 | €90.6 M | $93.79 M | -16.71% | 23667 |
| 12/29/2023 | €108.78 M | $120.06 M | -18.27% | 21904 |
| 12/30/2022 | €133.08 M | $142.43 M | -6.58% | 20076 |
| 12/30/2021 | €142.46 M | $161.91 M | -32.2% | 20099 |
| 12/31/2020 | €210.12 M | $256.64 M | 66.16% | 15400 |
| 12/31/2019 | €126.46 M | $141.8 M | 51.89% | 16369 |
| 12/31/2018 | €83.25 M | $95.46 M | -4.91% | 17502 |
| 12/29/2017 | €87.55 M | $105.01 M | -26.77% | 17722 |
| 12/30/2016 | €119.56 M | $125.72 M | 25.22% | 14871 |
Company Profile
Oryzon Genomics S.A. Overview
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders.
Key Product Candidates
- Iadademstat (ORY-1001): A selective LSD1 inhibitor currently in Phase II trials for oncology applications.
- Vafidemstat (ORY-2001): A CNS-optimized LSD1 inhibitor undergoing Phase II trials for CNS and psychiatric diseases.
- ORY-3001: An LSD1 inhibitor in preclinical development for non-oncological diseases.
Company Background
Founded in 2000, Oryzon Genomics is headquartered in Cornellà de Llobregat, Spain.
Frequently Asked Questions
-
What is Oryzon Genomics S.A.'s (BME-ORY) current market cap?As of 07/28/2025, Oryzon Genomics S.A. (including the parent company, if applicable) has an estimated market capitalization of $248.57 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Oryzon Genomics S.A. (BME-ORY) rank globally by market cap?Oryzon Genomics S.A. global market capitalization ranking is approximately 19003 as of 07/28/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.